Jose M. Arencibia

Jose M. Arencibia

Auto-generated profile, based on publicly available information

Jose M. Arencibia

Research Group PhosphoSites, Department of Internal Medicine I, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
JAJosé M. Arencibia
José M. Arencibia
DPDaniel Pastor-Flores
Daniel Pastor-Flores
ABAngelika F. Bauer
Angelika F. Bauer
JSJörg O. Schulze
Jörg O. Schulze
RBRicardo M. Biondi
Ricardo M. Biondi

1 September 2012 in Chemistry & Biology
Verified
Journal Article
Closed access
KBKatrien Busschots
Katrien Busschots
LLLaura A. Lopez-Garcia
Laura A. Lopez-Garcia
CLCarmen Lammi
Carmen Lammi
ASAdriana Stroba
Adriana Stroba
SZStefan Zeuzem
Stefan Zeuzem
RBRicardo M. Biondi
Ricardo M. Biondi

1 August 2015 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CSChristian Schmithals
Christian Schmithals
VKVerena Köberle
Verena Köberle
HKHüdayi Korkusuz
Hüdayi Korkusuz
TPThomas Pleli
Thomas Pleli
BKBianca Kakoschky
Bianca Kakoschky
APAlbrecht Piiper
Albrecht Piiper
IRGD is a derivative of the integrin-binding peptide RGD, which selectively increases the penetrability of tumor tissue to various coadministered substances in several preclinical models. In this study, we investigated the ability of iRGD to improve the delivery of sorafenib and doxorubicin therapy in hepatocellular carcinoma (HCC) using established mouse models of the disease. A contrast-enhanced MRI method was developed in parallel to assess the in vivo effects of iRGD in this setting. We found that iRGD improved the delivery of marker substances to the tumors of HCC-bearing mice about three-fold without a parallel increase in normal tissues. Control peptides lacking the critical CendR motif had no effect. Similarly, iRGD also selectively increased the signal intensity from tumors in Gd-DTPA–enhanced MRI. In terms of antitumor efficacy, iRGD coadministration significantly augmented the individual inhibitory effects of sorafenib and doxorubicin without increasing systemic toxicity. Overall, our results offered a preclinical proof of concept for the use of iRGD coadministration as a strategy to widen the therapeutic window for HCC chemotherapy, as monitored by Gd-DTPA–enhanced MRI as a noninvasive, clinically applicable method to identify iRGD-reactive tumors. Cancer Res; 75(15); 3147–54. ©2015 AACR.

9 November 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JOJose Antonio Ortega
Jose Antonio Ortega
LRLaura Riccardi
Laura Riccardi
EMElirosa Minniti
Elirosa Minniti
MBMarco Borgogno
Marco Borgogno
JAJose M. Arencibia
Jose M. Arencibia
MVMarco De Vivo
Marco De Vivo
We used a pharmacophore hybridization strategy to combine key structural elements of merbarone and etoposide and generated new type II topoisomerase (topoII) poisons. This first set of hybrid topoII poisons shows promising antiproliferative activity on human cancer cells, endorsing their further exploration for anticancer drug discovery.

6 August 1999 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KSKaroly Szepesházi
Karoly Szepesházi
GHGabor Halmos
Gabor Halmos
ASAndrew V. Schally
Andrew V. Schally
JAJosé M. Arencibia
José M. Arencibia
KGKate Groot
Kate Groot
EREulalia Rodriguez-Martin
Eulalia Rodriguez-Martin

1 June 2014 in Chemistry & Biology
Verified
Journal Article
Closed access
HZHua Zhang
Hua Zhang
SNSonja Neimanis
Sonja Neimanis
LLLaura A. Lopez-Garcia
Laura A. Lopez-Garcia
JAJosé M. Arencibia
José M. Arencibia
SASabine Amon
Sabine Amon
RBRicardo M. Biondi
Ricardo M. Biondi